Real world evidence has emerged as a transformative force in modern regulatory science, clinical pharmacology, health technology assessment, and patient centered drug development. As healthcare systems increasingly rely on data generated outside controlled clinical trials, regulators, payers, clinicians, and patients are confronted with both unprecedented opportunities and complex methodological challenges. This article presents a comprehensive theoretical and methodological synthesis of real world evidence generation and use, grounded strictly in the authoritative academic and policy literature that has shaped this field over the last decade. Drawing on foundational regulatory science frameworks, international best practice guidance, and evolving governance models, this work develops an integrated understanding of how real world data can be translated into scientifically credible and ethically responsible evidence for regulatory and health system decision making.

The paper situates real world evidence within the broader evolution of regulatory decision making, showing how traditional randomized controlled trials, while foundational, are increasingly insufficient to address the complexity, heterogeneity, and speed required in modern healthcare. Regulatory authorities such as the Food and Drug Administration and the European Medicines Agency have progressively embraced multidimensional evidence generation approaches that combine clinical trial data with observational data from registries, electronic health records, claims databases, and patient reported outcomes, as described by Jarow et al. 2017 and Liu et al. 2019. These developments are further reinforced by legislative reforms such as the Twenty First Century Cures Act, which explicitly encourages the use of real world evidence to support regulatory decisions and post market evaluation as explained by Gabay 2017.

This article advances a conceptual model that integrates regulatory science, patient focused drug development, and data governance into a unified analytical framework. It draws on patient engagement principles articulated by Perfetto et al. 2015 to show how real world evidence must not only satisfy methodological rigor but also reflect patient experiences, preferences, and outcomes. At the same time, it incorporates data governance and transparency principles developed by Cole et al. 2015, Berger et al. 2017, and the Equator Network 2024 to ensure that real world evidence is credible, reproducible, and fit for regulatory and health technology assessment purposes.

Methodologically, the article employs an interpretive qualitative synthesis of the provided references, using logic modeling approaches described by Frechtling 2007 and Van Koperen et al. 2013 to map the pathways through which real world data are transformed into regulatory grade evidence. This approach allows the identification of causal mechanisms, institutional incentives, and methodological constraints that shape the effectiveness of real world evidence in practice. Particular attention is given to trial designs using real world data, as elaborated by Baumfeld Andre et al. 2020, and to the integration of multiple data sources for health technology assessment as described by Graili et al. 2023.